Saller R, Hellenbrecht D
Cancer Treat Rep. 1985 Nov;69(11):1301-3.
The antiemetic effect of two benzamides, metoclopramide (MCL; Paspertin) and alizapride (AZP; Vergentan), was compared in two double-blind sequential analytical trials in cisplatin-treated patients (60-90 mg/m2). In the first trial, the drugs were given as loading infusions (0.5 mg/kg of body weight/hour over 2 hours) beginning 2 hours before cisplatin administration; the maintenance infusion (0.25 mg/kg/hour) given over 24 hours was half the dose (total dose, 7 mg/kg of body weight per treatment cycle). In the second trial, the dose of AZP was doubled. After nine and ten treatment pairs, MCL was significantly (2P less than 0.10) more effective than AZP: three of nine and four of ten patients receiving MCL remained totally free from vomiting, compared with only none of nine and one of ten patients receiving AZP. The incidence of extrapyramidal reactions was similar in all treatments. However, the administration of AZP was much more unfavorable because of moderate to severe hypotensive side effects.
在两项针对接受顺铂治疗（剂量为60 - 90mg/m²）患者的双盲序贯分析试验中，比较了两种苯甲酰胺类药物——甲氧氯普胺（MCL；胃复安）和阿立必利（AZP；呕必停）的止吐效果。在第一项试验中，在顺铂给药前2小时开始给予负荷输注（2小时内以0.5mg/kg体重/小时的速度输注）；24小时内给予的维持输注（0.25mg/kg/小时）剂量减半（每个治疗周期的总剂量为7mg/kg体重）。在第二项试验中，AZP的剂量加倍。在观察了9对和10对治疗病例后，MCL的疗效显著优于AZP（P＜0.10）：接受MCL治疗的9例患者中有3例、10例患者中有4例完全没有呕吐，而接受AZP治疗的9例患者中无一例、10例患者中仅有1例无呕吐。所有治疗组锥体外系反应的发生率相似。然而，由于存在中度至重度低血压副作用，AZP的应用更不理想。
